Pramipexole Teva 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
amended 
on 
IB/0052 
C.I.2.a - Change in the SPC, Labelling or PL of a 
05/11/2021 
PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
IA/0050 
A.7 - Administrative change - Deletion of 
22/12/2020 
manufacturing sites 
Annex II and 
PL 
IB/0049 
C.I.2.a - Change in the SPC, Labelling or PL of a 
04/06/2020 
26/06/2020 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II, Labelling 
and PL 
IA/0048 
B.II.b.3.a - Change in the manufacturing process of 
10/01/2020 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
IA/0047/G 
This was an application for a group of variations. 
31/10/2019 
n/a 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
N/0046 
Minor change in labelling or package leaflet not 
08/08/2019 
03/09/2019 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0045/G 
This was an application for a group of variations. 
20/06/2019 
n/a 
B.II.c.2.a - Change in test procedure for an excipient 
Page 2/16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- Minor changes to an approved test procedure 
B.II.f.1.e - Stability of FP - Change to an approved 
stability protocol 
IB/0044 
B.III.2.b - Change to comply with Ph. Eur. or with a 
29/01/2019 
n/a 
national pharmacopoeia of a Member State - Change 
to comply with an update of the relevant monograph 
of the Ph. Eur. or national pharmacopoeia of a 
Member State 
IB/0043 
C.I.2.a - Change in the SPC, Labelling or PL of a 
14/09/2018 
03/09/2019 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IAIN/0042/G 
This was an application for a group of variations. 
14/12/2017 
30/04/2018 
SmPC, Annex 
II and PL 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
IA/0041 
B.II.c.2.a - Change in test procedure for an excipient 
29/11/2017 
n/a 
- Minor changes to an approved test procedure 
IB/0040 
C.I.2.a - Change in the SPC, Labelling or PL of a 
30/05/2017 
30/04/2018 
SmPC and PL 
Page 3/16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0039 
A.5.b - Administrative change - Change in the name 
20/09/2016 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IAIN/0038/G 
This was an application for a group of variations. 
20/09/2016 
16/12/2016 
Annex II and 
PL 
A.5.a - Administrative change - Change in the name 
and/or address of a manufacturer/importer 
responsible for batch release 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0037 
C.I.2.a - Change in the SPC, Labelling or PL of a 
17/08/2016 
16/12/2016 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IA/0036 
B.III.2.b - Change to comply with Ph. Eur. or with a 
25/02/2016 
n/a 
national pharmacopoeia of a Member State - Change 
to comply with an update of the relevant monograph 
of the Ph. Eur. or national pharmacopoeia of a 
Page 4/16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Member State 
IB/0034/G 
This was an application for a group of variations. 
12/01/2016 
n/a 
B.II.b.3.z - Change in the manufacturing process of 
the finished or intermediate product - Other variation 
B.II.b.4.a - Change in the batch size (including batch 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
B.II.d.1.z - Change in the specification parameters 
and/or limits of the finished product - Other variation 
IAIN/0035/G 
This was an application for a group of variations. 
22/12/2015 
16/12/2016 
Annex II and 
PL 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.e.2.b - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Addition of a new specification 
parameter to the specification with its corresponding 
test method 
B.II.e.2.b - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Addition of a new specification 
parameter to the specification with its corresponding 
test method 
B.II.e.2.c - Change in the specification parameters 
and/or limits of the immediate packaging of the 
Page 5/16 
 
 
 
 
 
 
 
 
 
 
 
 
finished product - Deletion of a non-significant 
specification parameter (e.g. deletion of an obsolete 
parameter) 
B.II.e.2.c - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Deletion of a non-significant 
specification parameter (e.g. deletion of an obsolete 
parameter) 
B.II.e.4.a - Change in shape or dimensions of the 
container or closure (immediate packaging) - Non-
sterile medicinal products 
B.II.e.4.a - Change in shape or dimensions of the 
container or closure (immediate packaging) - Non-
sterile medicinal products 
IA/0033/G 
This was an application for a group of variations. 
27/05/2015 
n/a 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
T/0032 
Transfer of Marketing Authorisation 
09/01/2015 
27/01/2015 
SmPC, 
Labelling and 
PL 
IB/0030 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
24/09/2014 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
Page 6/16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0031 
B.III.1.a.1 - Submission of a new/updated or 
19/09/2014 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from 
an already approved manufacturer 
IB/0029 
B.II.c.2.d - Change in test procedure for an excipient 
30/07/2014 
n/a 
- Other changes to a test procedure (including 
replacement or addition) 
IB/0028 
Update of SmPC sections 4.4 and 4.8 to include 
02/06/2014 
27/01/2015 
SmPC and PL 
mania and delirium as adverse drug reactions and to 
add a new warning to inform healthcare 
professionals about the possibility of these events to 
occur under pramipexole treatment as well as the 
need for monitoring patients and dose adjustment. 
The Package Leaflet is updated accordingly. In 
addition, the contact details of LV, MT, LU, IS, CY 
and HU representatives have been updated. 
Furthermore, minor editorial corrections have been 
implemented in DA SmPC and ES SmPC and package 
leaflet. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
R/0027 
Renewal of the marketing authorisation. 
27/06/2013 
26/08/2013 
SmPC, Annex 
The CHMP reviewed the available data on the safety and 
Page 7/16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II, Labelling 
efficacy of pramipexole, including all variations introduced 
and PL 
since the marketing authorisation was granted, and based 
on these data considered that the risk-benefit balance of 
Pramipexole Teva in the treatment of the signs and 
symptoms of idiopathic Parkinson's disease, alone (without 
levodopa) or in combination with levodopa, i.e. over the 
course of the disease, through to late stages when the 
effect of levodopa wears off or becomes inconsistent and 
fluctuations of the therapeutic effect occur (end of dose or 
“on off” fluctuations) remains favourable. 
The CHMP recommended the renewal of the Marketing 
Authorisation with unlimited validity. 
II/0023 
Change to the specification of hardness of the 0.088 
21/03/2013 
21/03/2013 
mg tablets, and of hardness and thickness of the 
0.35 mg tablets. 
B.II.b.5.e - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Widening of the approved IPC limits, which 
may have a significant effect on overall quality of the 
finished product 
IB/0026/G 
This was an application for a group of variations. 
04/03/2013 
26/08/2013 
SmPC, Annex 
1. EMEA/H/C/xxxx/WS/0311: Update of section 4.8 of the 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
II, Labelling 
SmPC in order to include inappropriate antidiuretic 
and PL 
hormone secretion as an adverse drug reaction based on 
post-marketing data. Furthermore, the PI was brought in 
line with the latest QRD template version 8.0. 
2. EMEA/H/C/xxxx/WS/0326: Update of sections 4.4 and 
4.8 of the SmPC in order to update the safety information 
by implementing class labelling for the risk of impulse 
control disorders.  
Page 8/16 
 
 
 
 
 
 
 
 
 
 
 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
3. EMEA/H/C/xxxx/WS/0128: Section 4.8 of the SmPC has 
been updated based on new data to include ‘cardiac failure’ 
as a new side effect, and information has been added to 
section 4.8 about the estimation of frequencies for listed 
side effects observed post-marketing.  
The Package Leaflets were updated in accordance with the 
above. 
In addition, the list of local representatives has been 
updated. 
IA/0024 
B.I.a.3.a - Change in batch size (including batch size 
14/02/2013 
n/a 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the currently approved batch 
size 
IAIN/0022/G 
This was an application for a group of variations. 
07/12/2012 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer of the finished 
product, including quality control sites (excluding 
manufacturer for batch release) 
IA/0021/G 
This was an application for a group of variations. 
23/11/2012 
n/a 
B.II.e.3.b - Change in test procedure for the 
immediate packaging of the finished product - Other 
changes to a test procedure (including replacement 
or addition) 
Page 9/16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.e.3.b - Change in test procedure for the 
immediate packaging of the finished product - Other 
changes to a test procedure (including replacement 
or addition) 
B.II.e.3.b - Change in test procedure for the 
immediate packaging of the finished product - Other 
changes to a test procedure (including replacement 
or addition) 
B.II.e.2.a - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Tightening of specification limits 
IA/0020 
B.II.e.6.b - Change in any part of the (primary) 
23/11/2012 
n/a 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
IA/0019 
B.II.e.6.b - Change in any part of the (primary) 
23/11/2012 
n/a 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
IAIN/0018/G 
This was an application for a group of variations. 
13/11/2012 
n/a 
B.III.2.b - Change to comply with Ph. Eur. or with a 
national pharmacopoeia of a Member State - Change 
to comply with an update of the relevant monograph 
of the Ph. Eur. or national pharmacopoeia of a 
Member State 
B.III.2.b - Change to comply with Ph. Eur. or with a 
national pharmacopoeia of a Member State - Change 
Page 10/16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
to comply with an update of the relevant monograph 
of the Ph. Eur. or national pharmacopoeia of a 
Member State 
B.III.2.b - Change to comply with Ph. Eur. or with a 
national pharmacopoeia of a Member State - Change 
to comply with an update of the relevant monograph 
of the Ph. Eur. or national pharmacopoeia of a 
Member State 
B.III.2.a.1 - Change of specification('s) of a former 
non Pharmacopoeial substance to comply with the 
Ph. Eur. or with a national pharmacopoeia of a 
Member State - AS 
IB/0016 
B.II.b.1.e - Replacement or addition of a 
10/05/2012 
n/a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
packaging, for non-sterile medicinal products 
IB/0015 
B.II.b.1.z - Replacement or addition of a 
08/05/2012 
n/a 
manufacturing site for the FP - Other variation 
IA/0014/G 
This was an application for a group of variations. 
16/03/2012 
n/a 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
Page 11/16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
specification limits 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
IB/0013 
B.II.a.3.z - Changes in the composition (excipients) 
07/12/2011 
n/a 
of the finished product - Other variation 
IA/0012/G 
This was an application for a group of variations. 
28/10/2011 
n/a 
B.II.a.3.b.1 - Changes in the composition 
(excipients) of the finished product - Other excipients 
- Any minor adjustment of the quantitative 
composition of the finished product with respect to 
excipients 
B.II.b.4.a - Change in the batch size (including batch 
size ranges) of the finished product - Up to 10-fold 
compared to the currently approved batch size 
IA/0011 
B.II.d.2.a - Change in test procedure for the finished 
24/08/2011 
n/a 
product - Minor changes to an approved test 
procedure 
IB/0010/G 
This was an application for a group of variations. 
28/01/2011 
n/a 
SmPC, Annex 
Sections 4.2, 4.5, 4.6, 4.8 and 5.3 of the SPC of 
Variation type IB, C.I.3.a 
Update of the SPC section 4.5 to include the results 
of an in depth evaluation of h0CT2 inhibitors 
(implementation of agreed wording of FUMs for Sifrol 
amd Mirapexin) and SPC section 4.8 to include new 
II and PL 
Pramipexole Teva were updated to align it with that of the 
reference medicinal product. Sections 2 and 4 of the 
Package leaflet were updated accordingly. This followed 
changes to the SPC of the reference medicinal product 
(Sifrol) via the following procedures: 
EMEA/H/C/133/WS/0041/G and EMEA/H/C/133/WS/0061.  
Page 12/16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
side effects and revise frequency categories on 
assessment of PSUR 13.  
The Package Leaflet has been updated accordingly. 
Variation type IB, C.I.3.a 
Update of Section 5.3 of SPC to include non-clinical 
information concerning delayed sexual development 
observed in rats as agreed in the assessment of 
FUMs for Sifrol / Mirapexin. 
In addition, minor typographical errors in the 
Annexes have been amended for PT, LV and CS 
languages and updates to the local representatives 
list in the PIL is also being made. 
Annexes  I-III have been updated accordingly. As 
previously agreed, Annex II.B have also been 
updated in line with the October and November 
CHMP procedural announcement. 
C.I.3.a - Implementation of change(s) requested 
following the assessment of an USR, class labelling, a 
PSUR, RMP, FUM/SO, data submitted under A 45/46, 
or amendments to reflect a Core SPC - Changes with 
NO new additional data are submitted by the MAH 
C.I.3.a - Implementation of change(s) requested 
following the assessment of an USR, class labelling, a 
PSUR, RMP, FUM/SO, data submitted under A 45/46, 
or amendments to reflect a Core SPC - Changes with 
NO new additional data are submitted by the MAH 
In addition, Annex II was updated to reflect the revised 
template for the description of the DDPS and the list of 
local representatives in the Package Leaflet was updated. 
Page 13/16 
 
 
 
 
 
 
 
 
 
 
IA/0008/G 
This was an application for a group of variations. 
09/12/2010 
09/12/2010 
SmPC, 
Labelling and 
PL 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
Page 14/16 
 
 
 
 
 
 
 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
N/0009 
The Marketing Authorisation Holder (MAH) took the 
26/11/2010 
n/a 
PL 
opportunity to update details of local representatives 
in Annex IIIB. 
Minor change in labelling or package leaflet not 
connected with the SPC (Art. 61.3 Notification) 
IB/0006 
B.II.a.2.a - Change in the shape or dimensions of the 
19/10/2010 
n/a 
SmPC and PL 
pharmaceutical form - Immediate release tablets, 
capsules, suppositories and pessaries 
IB/0005 
B.II.a.1.a - Change or addition of imprints, bossing 
19/10/2010 
n/a 
SmPC and PL 
or other markings including replacement, or addition 
of inks used for product marking - Changes in 
imprints, bossing or other markings 
IA/0007 
A.5.a - Administrative change - Change in the name 
13/09/2010 
n/a 
Annex II and 
and/or address of a manufacturer responsible for 
PL 
batch release 
IA/0004 
IA_07_a_Replacement/add. of manufacturing site: 
14/10/2009 
n/a 
Secondary packaging site 
II/0003 
Update, in line with the reference medicinal product 
23/07/2009 
20/08/2009 
SmPC and PL 
Section 4.8 of the SPC of Pramipexole Teva was updated to 
of section 4.8 of the Summary of Product 
Characteristics to include the terms "dyspnoea" and 
"pneumonia". The Package Leaflet is being updated 
accordingly. In addition, the list of local 
align it with that of the reference medicinal product. This 
followed changes to the SPC of the reference medicinal 
products via the following procedure: EMEA/H/C/133/II/52 
(Sifrol). 
Page 15/16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
representatives was added to the Package Leaflet. 
Update of Summary of Product Characteristics and 
Package Leaflet 
II/0001 
Update of Summary of Product Characteristics and 
23/04/2009 
20/05/2009 
SmPC and PL 
Package Leaflet 
IA/0002 
IA_08_b_01_Change in BR/QC testing - repl./add. 
15/05/2009 
n/a 
Annex II and 
manuf. responsible for BR - not incl. BC/testing 
PL 
Page 16/16 
 
 
 
 
 
 
 
 
 
 
 
 
